2,3-Benzodiazepine Derivatives as non-competitive AMPA

Abstract

Derivatives of 2,3-benzodiazepine are substituted by one or two halogen atom(s) and have the general formula ##STR1## These derivatives are non-competitive AMPA antagonists and are used in pharmaceutical compositions. A process to make the 2,3-benzodiazepine derivatives includes converting starting compounds which are substituted by one or two halogen groups and have the general formula ##STR2##

Claims

1. A compound of the formula I ##STR3## wherein R.sup.1 and R.sup.2 represent, independently, a hydrogen, a halogen, a C.sub.1-4 alkyl group, a C.sub.1-4 alkoxy group, a nitro group, a trifluoromethyl group or a group of the formula --NR.sup.8 R.sup.9,

wherein R.sup.8 and R.sup.9 represent, independently, a hydrogen, a C.sub.1-4 alkyl group or a group of the formula --COR.sup.10,

wherein R.sup.10 is a hydrogen, a C.sub.1-6 alkyl group that can be substituted, a C.sub.6-10 aryl group, a C.sub.1-4 alkoxy group, a C.sub.3-5 cycloalkyl group, a C.sub.2-6 alkenyl group, a C.sub.3-5 cyclo-alkoxy group or a group of the formula --NR.sup.11 R.sup.12,

wherein R.sup.11 and R.sup.12 represent, independently, a hydrogen, a C.sub.1-4 alkyl group, a C.sub.3-5 cycloalkyl group or a C.sub.6-10 aryl group,

wherein R.sup.3 represents a C.sub.1-4 alkyl group, a C.sub.3-5 cycloalkyl group or a group of the formula --CO--R.sup.13, wherein R.sup.13 has the same definitions given in relation to R.sup.10,

wherein R.sup.4 and R.sup.5 represent, independently, a hydrogen or a C.sub.1-3 alkyl group,

wherein R.sup.6 and R.sup.7, are, independently, a hydrogen, a chloro or a bromo,

wherein R.sup.6 and R.sup.7 are not both hydrogen,

and the isomers of said compound and acid addition salts of said compound and of said isomers.

2. A compound which is 3-Acetyl-1-(4-aminophenyl)-8-chloro-4-methyl-4,5-dihydro-3H-2,3-benzodiaze pine.

3. A compound which is 1-(4-Aminophenyl)-8-chloro-4-methyl-3-methyl-carbamoyl-4,5-dihydro-3H-2,3- benzodiazepine.

4. A pharmaceutical composition comprising a compound of the formula I ##STR4## wherein R.sup.1 to R.sup.7 are as defined in claim 1, or an isomer of said compound or a pharmaceutically acceptable acid addition salt of said compound or said isomer.

5. A pharmaceutical composition comprising the compound as defined in claim 4, and further comprising at least one member selected from the group consisting of conventional carriers, solvents, diluents and excipients used in the preparation of pharmaceutical compositions.

6. A method of treating diseases accompanied by muscle spasticity comprising

administering to a mammal in need thereof an effective amount of the compound defined in claim 1.

7. A method of treating epilepsy comprising

administering to a mammal in need thereof an effective amount of the compound defined in claim 1.

8. A method of treating acute or chronic neurodegenerative diseases comprising

administering to a mammal in need thereof an effective amount of the compound defined in claim 1.

9. A process for the preparation of compounds of formula I ##STR5## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, and R.sup.7 have the same meaning as in claim 1, and

the isomers of said compound and acid addition salts of said compound, comprising

introducing the R.sup.3 group into position 3 of a compound of formula II ##STR6## wherein R.sup.1, R.sup.2, R.sup.4, R.sup.5, R.sup.6, and R.sup.7 are as stated above, and, optionally converting a compound of the formula I into an acid addition salt of said compound or setting free said compound of the formula I from an acid addition salt.

10. A compound of formula II ##STR7## wherein R.sup.1 and R.sup.2 represent, independently, a hydrogen, a halogen, a C.sub.1-4 alkyl group, a C.sub.1-4 alkoxy group, a nitro group, a trifluoromethyl group or a group of the formula --NR.sup.8 R.sup.9,

wherein R.sup.8 and R.sup.9 represent, independently, a hydrogen, a C.sub.1-4 alkyl group or a group of the formula --COR.sup.10,

wherein R.sup.10 is a hydrogen, a C.sub.1-6 alkyl group that can be substituted, a C.sub.6-10 aryl group, a C.sub.1-4 alkoxy group, a C.sub.3-5 cycloalkyl group, a C.sub.2-6 alkenyl group, a C.sub.3-5 cyclo-alkoxy group or a group of the formula --NR.sup.11 R.sup.12, wherein R.sup.11 and R.sup.12 represent, independently, a hydrogen, a C.sub.1-4 alkyl group, a C.sub.3-5 cycloalkyl group or a C.sub.6-10 aryl group,

wherein R.sup.3 represents a hydrogen,

wherein R.sup.4 and R.sup.5 represent, independently, a hydrogen or a C.sub.1-3 alkyl group,

wherein R.sup.6 and R.sup.7 are, independently, a hydrogen, a chloro or a bromo,

wherein R.sup.6 and R.sup.7 are not both hydrogen.

11. A method of non-competitively antagonizing an amino acid receptor comprising

administering to a mammal in need thereof an effective amount of the compound defined in claim 1.

12. The method as defined in claim 11 wherein the amino acid receptor is an AMPA receptor.